

# **Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update**

<https://marketpublishers.com/r/IF147D0652EAEN.html>

Date: December 2022

Pages: 83

Price: US\$ 3,500.00 (Single User License)

ID: IF147D0652EAEN

## **Abstracts**

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### **SUMMARY**

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Interleukin-1 receptor-associated kinase 4 (IRAK-4) is a protein kinase involved in signaling innate immune responses from Toll-like receptors. Mutations in IRAK-4 result in IRAK4 deficiency and recurrent invasive pneumococcal disease. It phosphorylates E3 ubiquitin ligases Pellino proteins to promote pellino-mediated polyubiquitination of IRAK1. Ubiquitin-binding domain of IKBKG/NEMO binds to polyubiquitinated IRAK1 bringing together the IRAK1-MAP3K7/TAK1-TRAF6 complex and the NEMO-IKKA-IKKB complex. MAP3K7/TAK1 activates IKKs leading to NF-kappa-B nuclear translocation and activation.

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) pipeline Target constitutes close to 24 molecules. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 8, 10 and 2 respectively. Report covers products from therapy areas Immunology, Oncology, Dermatology, Gastrointestinal, Metabolic Disorders, Cardiovascular, Central Nervous System, Infectious Disease, Musculoskeletal Disorders and Undisclosed which

include indications Rheumatoid Arthritis, Inflammation, Atopic Dermatitis (Atopic Eczema), Myelodysplastic Syndrome, Autoimmune Disorders, Diffuse Large B-Cell Lymphoma, Psoriasis, Chronic Myelomonocytic Leukemia (CMML), Follicular Lymphoma, Hidradenitis Suppurativa, Inflammatory Bowel Disease, Lymphoma, Unspecified Cancer, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Chronic Lymphocytic Leukemia (CLL), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous Lupus Erythematosus, Diabetic Nephropathy, Esophageal Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gouty Arthritis (Gout), Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Lupus Erythematosus, Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Multiple Sclerosis, Pancreatic Ductal Adenocarcinoma, Primary CNS Lymphoma, Rosacea, Solid Tumor, Systemic Lupus Erythematosus, Type 1 Diabetes (Juvenile Diabetes) and Unspecified.

The latest report Interleukin 1 Receptor Associated Kinase 4 - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1)

The report reviews Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN

64 or IRAK4 or EC 2.7.11.1) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Overview

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Companies Involved in Therapeutics Development

Asahi Kasei Pharma Corp

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Bayer AG

Beijing Hanmi Pharmaceutical Co Ltd

Bristol-Myers Squibb Co

Chia Tai Tianqing Pharmaceutical Group Co Ltd

Emmaus Life Sciences Inc

Evommune Inc

Fresh Tracks Therapeutics Inc

Gilead Sciences Inc

Kurome Therapeutics Inc

Kymera Therapeutics Inc

Nyrada Inc

Pfizer Inc

Rigel Pharmaceuticals Inc

TG Therapeutics Inc

Xi'An Yufan Biotechnology Co Ltd

Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or

IRAK4 or EC 2.7.11.1) - Drug Profiles

AK-179 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AS-2444697 - Drug Profile

Product Description

Mechanism Of Action

History of Events

AZD-6793 - Drug Profile

Product Description

Mechanism Of Action

BAY-1830839 - Drug Profile

Product Description

Mechanism Of Action

History of Events

BMS-986126 - Drug Profile

Product Description

Mechanism Of Action

History of Events

emavusertib hydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

EVO-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

FRTX-02 - Drug Profile

Product Description

Mechanism Of Action

History of Events

GS-5718 - Drug Profile

Product Description

Mechanism Of Action

History of Events

IRAK4 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KM-10544 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KT-413 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KT-474 - Drug Profile

Product Description

Mechanism Of Action

History of Events

R-289 - Drug Profile

Product Description

Mechanism Of Action

History of Events

R-835 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecule to Inhibit IRAK4 for Rheumatoid Arthritis and Unspecified Cancer - Drug Profile

Product Description

Mechanism Of Action

Small Molecules 1 to Inhibit IRAK4 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit IRAK1 and IRAK4 for Acute Myelocytic Leukemia and Myelodysplastic Syndrome - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Inhibit IRAK4 for Autoimmune Disorders, Cardiovascular Disease, Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit IRAK4 for Inflammation - Drug Profile

Product Description  
Mechanism Of Action  
History of Events  
TQH-3821 - Drug Profile  
Product Description  
Mechanism Of Action  
zabedoseritib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
zimlovisertib - Drug Profile  
Product Description  
Mechanism Of Action  
History of Events  
ZYF-0116 - Drug Profile  
Product Description  
Mechanism Of Action  
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Dormant Products  
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Discontinued Products  
Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) - Product Development Milestones  
Featured News & Press Releases  
Appendix  
Methodology  
Coverage  
Secondary Research  
Primary Research  
Expert Panel Validation  
Contact Us  
Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

## I would like to order

Product name: Interleukin 1 Receptor Associated Kinase 4 (Renal Carcinoma Antigen NY REN 64 or IRAK4 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/IF147D0652EAEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/IF147D0652EAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970